JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Diagnostic white blood cells can be a predictor for mutation existence in myelodisplastic syndromes: the role of next generation sequencing
Abstract
Aims: Myelodisplastic syndromes (MDS) are hematological disorders originating from clonal damage and characterized by inefficient bone marrow activity. The existence of mutations has been shown to play a significant role in risk, treatment response, turnover to acute myeloid leukemia, prognosis, and overall survival. Next-generation sequencing (NGS) is a technique that detects gene mutations and has been the subject of studies for detecting MDS-related mutations.
Methods: We conducted a study on 33 MDS patients during the period of 2021–2023. Patients were analyzed for the existence of mutations with the NGS technique, and the hematological parameters, transfusion need, IPSS, and IPSS-R scores of these patients were recorded.
Results: 15 out of 33 patients (45.5%) were tested for mutations. WBC levels at the diagnosis of patients with type 1 number somatic mutations were higher than in other groups, 7056.25, 2416.67/µL, and 3036.67/µL, respectively (p = 0.048). The ratio of neutrophil and lymphocyte values recorded and NGS positive were higher than those tested negative (1.56 and 3.51, respectively). Patients with the type 1 mutation had higher WBC levels than patients with the type 2 and type 3 mutations, 7056.25/µL, 2416.67/µL, and 3036.67/µL, respectively. 
Conclusion: Genetic mutations are common in MDS patients, and NGS is a useful tool to detect them. Understanding the role of mutations in the matter of risk classification, treatment response, and prognosis is quite important, and larger-scale studies are needed.

Keywords : MDS, myelodisplastic syndromes, NGS, next generation sequencing

Download Article


1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239-2252. doi:10.1016/S0140-6736(13)61901-61907
2. Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control. 2008;15(Suppl):4-13. doi:10.1177/107327480801504s02
3. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European Leukemia Net. Blood. 2013;122(17):2943-2964. doi:10.1182/blood-2013-03-492884
4. Tran TB, Siddon AJ. Molecular findings in myeloid neoplasms. Int J Lab Hematol. 2023;45(4):442-448. doi:10.1111/ijlh.14118
5. Tria FP 4th, Ang DC, Fan G. Myelodysplastic syndrome: diagnosis and screening. Diagnostics (Basel). 2022;12(7):1581. doi:10.3390/diagnostics 12071581
6. Li J, Pei L, Liang S, et al. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: a multi-center study from China. Cancer Med. 2023;12(8):9332-9350. doi:10. 1002/cam4.5690
7. Yang H, Garcia-Manero G, Sasaki K, et al. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022;36(9):2306-2316. doi:10.1038/s41375-022-01652-8
8. Ramos PM, Choi J, Campbell CD, et al. Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial. EJHaem. 2023;4(3):876-881. doi:10. 1002/jha2.694
9. Yu J, Li Y, Li T, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020;9:2. doi:10.1186/s40164-019-0158-5
10. Tobiasson M, Kittang AO. Treatment of myelodysplastic syndrome in the era of next-generation sequencing. J Intern Med. 2019;286(1):41-62. doi:10.1111/joim.12893
11. Abbas HA, Reville PK, Jiang X, et al. Response to hypomethylating agents in myelodysplastic syndrome is associated with emergence of novel TCR clonotypes. Front Immunol. 2021;12:659625. doi:10.3389/fimmu.2021.659625
12. Takahashi K, Wang F, Sahil S, et al. Presence of 4 or more driver mutations predicts poor response to hypomethylating agent (HMA) therapy and poor overall survival in MDS. Blood. 2015;126:1663-1663. doi:10.1182/blood.V126.23.1663.1663.
13. Thol F, Platzbecker U. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Adv. 2019;3(21):3449-3453. doi:10.1182/bloodadvances.2018022434
14. Kawata E, Lazo-Langner A, Xenocostas A, et al. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. Br J Haematol. 2021;192(4):729-736. doi:10. 1111/bjh.16891
Article available in :
Volume 2, Issue 4, 2024
Page : 87-92
https://doi.org/10.51271/JCHOR-0046
Article Information
Received : 09 Tem 2024
Accepted : 16 Ağu 2024
Published : 14 Kas 2024
Corresponding Author :

Ayşe Günay: Department of Clinical Pharmacy, Konya City Hospital, Konya, Turkiye

[email protected]
Citation : Yılmaz S, Günay A, Cırık S, Baştürk A, Başdemirci M, Balasar Ö. Diagnostic white blood cells can be a predictor for mutation existence in myelodisplastic syndromes: the role of next generation sequencing. J Curr Hematol Oncol Res. 2024;2(4):87-92.

Read: 60
Download : 866
Cited: 0
_Footer